Company Financials
AntiCA Biomed has received commitment of seeding investment, which is sufficient for the first 1.5 years to conduct its pilot clinical trials, however additional funding would be required to increase significantly number of patients included in the clinical trials, and conduct preclinical research for the development of the rejuvenation technology (based on the same main basis as cancer treatment approach) prior to its clinical assessment efficacy.
There are 18-35 mln people in the world with oncological diseases and every year another 8-10 mln people to add to that number. Almost 10 million people die from cancer every year. There is an urgent need to develop efficient and non-toxic cancer therapy.
AntiCA Biomed plans to conduct its first clinical trials in 2021 and continue in 2022. Upon its successful completion of its clinical trials the Company projects to setup its first Cancer Treatment Center in 2023 allowing patients met inclusion/exclusion criteria and upon IRB approval to receive experimental treatment, especially in cases when traditional treatments hasn’t show satisfying efficacy or fail to treat patients and start monetize its technology. Reprogramming Formula is not very expensive but financially successful cure is hard to overestimate. Cost of the treatment for the patients still to be determined. People with cancer family history or elderly can be treated preventively as well.
Treatment of patients at the Cancer Treatment Center will provide revenue for investors and also additional funds to accelerate the Company research program on Systemic Rejuvenation planned to be conducted in San Diego. Investors will have priority and favorable conditions to receive treatments subject to successful completion of planned clinical trials.
